Promising therapeutic tool for AMPH-induced addiction, reducing the oxidative stress, attenuating evoked (MA and heat HA) and spontaneous pain (FST) phenotypes, and all phases of morphine-induced behavioral locomotor sensitization in mice

Estrogen receptor α (ERα) ligand as potent antiestrogen; Metabolite of tamoxifen

Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $44.55 Total: $4,455.00 50 $51.48 Total: $2,574.00 25 $60.39 Total: $1,509.75 10 $71.28 Total: $712.80 5 $84.15 Total: $420.75

Novel anti-thrombosis agent, orally inhibiting venous thrombosis and arterial thrombosis in vivo, showing no bleeding risk

Novel lysophosphatidic acid receptor 3 (LPA3) agonist

Orphan nuclear receptor DAF-12 ligand, inhibiting the dauer-promoting activity of DAF-12

Novel water-sensitive probe, demonstrating superior sensitivity for detecting modulation of water microsolvation, structural conformation during oligomer formation and 5FUrd binding to both wild type and mutant SOD1

Building Block

Negative control for RSL3

Potent antagonist of GluN2B-NMDA receptors (Ki = 5.8 nM), inhibiting ion flux in two-electrode voltage clamp experiments (IC50 = 223 nM)

Novel prodrug of the sigma (σ) ligand haloperidol metabolite II conjugated with the histone deacetylase (HDAC) inhibitor valproic acid, demonstrating antiangiogenic activity

Novel profluorescent RAMOSUS3 (RMS3) probe with strigolactone-like bioactivity

Potent and selective 5-HT2 serotonin receptor agonist

Inhibitor of ADP-induced platelet aggregation; anti-thrombotic

Novel potassium channel opener

Novel angiogenesis inhibitor, regulating endothelial cell fate and angiogenesis

Novel probe for mycobacterial and fungal carbonic anhydrase

Catecholamine-depleting agent, actively against the 3 major monoamines in the CNS

Novel potent anti-malarial agent against multiple resistant strains of P. falciparum in vitro and show no cytotoxicity to mammalian cells

A potent and selective Adenosine receptor A2A agonist

Seletalisib (UCB5857) is potent and selective PI3Kδ inhibitor with an IC50 of 12 nM.

A highly potent, selective and orally bioavailable trace amine-associated receptor 1 (TRRA1) full agonist with EC50 of 18 nM, >500-fold selectivity over human adrenergic α2A receptor.

LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

JMV 2959 (AEZS-123) is a potent ghrelin receptor (GHS-R1A) antaognist with binding IC50 of 32 nM.

Nutlin-3a is arbitrarily referred to as enantiomer a because it appears as the first peak from chiral purification of racemic nutlin-3 and its absolute stereocenter assignment is not known.

IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma.

Netarsudil (AR-13324) is a potent, selective ROCK inhibitor with Ki of 4.2 nM for ROCK2.

PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity.

CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1.

Fmk is an irreversible ribosomal S6 kinase inhibitor 1/2 inhibitor.